In Levaquin Patent Battle, Daiichi Scores Again

Law360, New York (March 20, 2006, 12:00 AM EST) -- In its second big win in a high-stakes patent battle over the anti-infective drug Levaquin, Japanese drug maker Daiichi Pharmaceutical Co. has been granted summary judgment on its motion for no inequitable conduct, effectively tossing a bid by four generic challengers to duplicate the blockbuster drug.

The suit, brought by Daiichi, Johnson & Johnson, and Ortho-Mcneil Pharmaceutical Inc., has been ongoing in the U.S. District Court in New Jersey since June 2002.

The case stemmed from Abbreviated New Drug Application (ANDA) filings made by Teva Pharmaceuticals...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.